Novartis upgrades mid-term guidance

 

• Mid-term sales guidance upgraded to +6% CAGR 2023-2028 and +5% 2024-2029
  
  
• Strong momentum in the business with 8 in-market brands with USD 3bn+ to USD 8bn+ peak sales potential and 15+ near-term submission-enabling readouts
  
  
• 30+ high-value medicines in the pipeline expected to support continued mid-single digit sales growth beyond 2029

https://www.globenewswire.com/news-release/2024/11/21/2984888/0/en/Novartis-upgrades-mid-term-guidance-and-highlights-deep-pipeline-in-core-therapeutic-areas-to-drive-long-term-growth.html